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Tumor Necrosis Factor-a-induced Insulin Resistance in 3T3-L1
Adipocytes Is Accompanied by a Loss of Insulin Receptor
Substrate-1 and GLUT4 Expression without a Loss of Insulin
Receptor-mediated Signal Transduction*
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Jacqueline M. Stephens‡, Jongsoon Lee, and Paul F. Pilch§
From the Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118

A number of studies have demonstrated that tumor
necrosis factor-a (TNF-a) is associated with profound
insulin resistance in adipocytes and may also play a
critical role in the insulin resistance of obesity and noninsulin-dependent diabetes mellitus. Reports on the
mechanism of TNF-a action have been somewhat contradictory. GLUT4 down-regulation has been implicated
as a possible cause of insulin resistance as has been the
reduced kinase function of the insulin receptor. Here we
examine the effects of tumor necrosis factor on the protein components thought to be involved in insulin-stimulated glucose transport in adipocytes, namely the insulin receptor, its major substrate IRS-1, and the insulin
responsive glucose transporter GLUT4. Prolonged exposure (72–96 h) of 3T3-L1 adipocytes to TNF-a causes a
substantial reduction (>80%) in IRS-1 and GLUT4 mRNA
and protein as well as a lesser reduction (>50%) in the
amount of the insulin receptor. Nevertheless, the remaining proteins appear to be biochemically indistinguishable from those in untreated adipocytes. Both the
insulin receptor and IRS-1 are tyrosine-phosphorylated
to the same extent in response to acute insulin stimulation following cellular TNF-a exposure. Furthermore,
the ability of the insulin receptor to phosphorylate exogenous substrate in the test tube is also normal following its isolation from TNF-a-treated cells. These results
are confirmed by the reduced but obvious level of insulindependent glucose transport and GLUT4 translocation
observed in TNF-a-treated adipocytes. We conclude that
the insulin resistance of glucose transport in 3T3-L1
adipocytes exposed to TNF-a for 72–96 h results from a
reduced amount in requisite proteins involved in insulin action. These results are consistent with earlier studies indicating that TNF-a reduces the transcriptional
activity of the GLUT4 gene in murine adipocytes, and
reduced mRNA transcription of a number of relevant
genes may be the general mechanism by which TNF-a
causes insulin resistance in adipocytes.
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Insulin resistance is defined as the inability of cells or tissues
to respond to physiological levels of insulin and is a characteristic condition of early stage non-insulin-dependent diabetes
mellitus (1). Insulin resistance has also been described in a
number of disease conditions including cancer, sepsis, endotoxemia, trauma, and alcoholism. These latter situations are
known to cause altered levels of cytokine expression whose
actions, in part, may lead to the establishment of the pathophysiological state (2). In particular, tumor necrosis factor-a
(TNF-a)1 secretion from activated macrophages has been recognized as one of the initial responses in these disease states.
Evidence from both whole-animal and cell culture studies indicate that TNF-a alters protein and lipid metabolism in adipose tissue and in skeletal muscle, the insulin target tissues
whose lack of hormonal response would result in insulin resistance (2, 3). Studies in cultured cells have demonstrated that
many cytokines can regulate glucose transport (4, 5) and
TNF-a, in particular, causes the decreased expression of the
insulin-sensitive glucose transporter GLUT4 (6). However, it is
not completely clear whether this accounts for organismal insulin resistance, since muscle GLUT4 levels are normal in
insulin-resistant rodents and humans (7–9).
On the other hand, numerous recent studies have implicated
the involvement of TNF-a in insulin resistance in adipocytes in
culture as well as in whole-animal models. As noted above,
TNF-a treatment of cultured murine adipocytes (3T3-L1s) for
several days results in a significant repression of GLUT4 transcription and expression, resulting in a condition of insulin
resistance without a depletion of lipid content or a change in
other fat-specific genes such as lipoprotein lipase (6). In vivo
studies have demonstrated that the adipose tissue of obese
insulin-resistant rodents (10) and obese humans (11, 12) has a
significant increase in TNF-a production and that neutralization of TNF-a in insulin-resistant rodents results in an increase
in the peripheral uptake of glucose in response to insulin (10).
Thus, a role for TNF-a in some types of insulin resistance
appears quite likely, and therefore understanding its mechanism of action will be important. One mechanism that has been
suggested for TNF-a-induced insulin resistance is inhibition of
signaling from the insulin receptor (13, 14). Both a defect in the
ability of the insulin receptor to autophosphorylate and a loss of
its ability to phosphorylate, on tyrosine residues, its major
substrate, insulin receptor substrate-1 (IRS-1) has been reported (13, 14). More recently, TNF-a has been reported to
induce serine phosphorylation of IRS-1 which, in turn, inhibits
the insulin receptor from phosphorylating this substrate (15). A

1
The abbreviations used are: TNF-a, tumor necrosis factor-a; TNF,
tumor necrosis factor; IRS-1, insulin receptor substrate-1; DMEM, Dulbecco’s modified Eagle’s medium.
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precedent for this mechanism comes from studies of the phosphatase inhibitor okadaic acid, which has been shown to cause
serine phosphorylation of IRS-1 and a subsequent inhibition of
insulin receptor signaling (16). This biochemical mechanism
makes sense for the rapid regulation of insulin signaling by
TNF-a (17, 18) and okadaic acid (16), because phosphorylation/
dephosphorylation are rapid (seconds to minutes) events. However, the effect of chronic TNF-a treatment (96 –120 h) would
seem less likely to utilize such a mechanism. Moreover, although GLUT4 is significantly down-regulated after 96 h of
adipocyte TNF-a exposure, there is still some residual insulinstimulated glucose transport (6) (see Table II).
Thus, in the present study, we have used insulin-sensitive
glucose uptake as an assay for insulin-dependent signal transduction to examine the development of TNF-a-induced insulin
resistance. We see no evidence for any changes in the overall
tyrosine phosphorylation states of the insulin receptor or its
major substrate, IRS-1. On the other hand, TNF-a-induced
insulin resistance appears to involve down-regulation of several of the known component proteins required for insulinstimulated glucose transport. These include GLUT4, IRS-1,
and to a lesser extent the insulin receptor.
EXPERIMENTAL PROCEDURES

Materials—Recombinant human TNF-a was from Biogen. Murine
TNF-a was purchased from Quality Control Biochemicals. All experiments were performed with both human and murine TNF-a, and identical results were obtained with both the murine and human cytokine.
Dulbecco’s modified Eagle’s medium (DMEM) was purchased from BioWhittaker, Inc. Bovine and fetal bovine serum were obtained from
Hyclone and Life Technologies, Inc., respectively. Wheat germ agglutinin-coupled agarose was obtained from E. Y. Laboratories. [g-32P]ATP
and [3H]2-deoxyglucose were acquired from Dupont NEN. All other
chemicals were purchased from Sigma unless otherwise noted.
Cell Culture—Murine 3T3-L1 preadipocytes were cultured, maintained, and differentiated as described previously (19). Briefly, cells
were plated and grown for 2 days postconfluence in DMEM supplemented with 10% calf serum. Differentiation was then induced by
changing the medium to DMEM supplemented with 10% fetal bovine
serum, 0.5 mM 3-isobutyl-1-methylxanthine, 1 mM dexamethasone, and
1.7 mM insulin. After 48 h, the differentiation medium was replaced
with maintenance medium containing DMEM supplemented with 10%
fetal bovine serum. The maintenance medium was changed every 48 h
until the cells were utilized for experimentation. Human or murine
TNF-a was dissolved in phosphate-buffered saline containing 0.1%
fatty acid-free and growth factor-depleted bovine serum albumin (Sigma) and was added to the cell culture media 7 days after the induction
of differentiation when greater than 95% of the cells had the morphological and biochemical properties of adipocytes. In the case of prolonged TNF-a treatment (.1 day), fully differentiated 3T3-L1 adipocytes were treated every 24 h with the cytokine.
3T3-L1 Cell Membrane Fractionation—Prior to harvesting, cells
were thoroughly rinsed at 37 °C with DMEM and then incubated in
fresh serum-deprived DMEM for 2– 4 h. Untreated and TNF-a-treated
3T3-L1 adipocytes were rinsed with Buffer A (250 mM sucrose, 20 mM
HEPES, 1 mM EDTA, pH 7.4) at 37 °C and then harvested at 4 °C in
Buffer A and homogenized with a Teflon pestle. Total membranes were
pelleted at 250,000 3 g for 90 min and resuspended in Buffer B (20 mM
HEPES, 1 mM EDTA, pH 7.4). The cytosolic supernatant was also saved
for further analysis. For some experiments, membranes were fractionated according to the protocol of Clancy and Czech (20) into plasma
membrane, intracellular membranes, and a nuclear/mitochondrial fraction as we have previously described (6). Membrane and cytosolic fractions were divided and immediately stored at 270 °C. Both Buffer A
and Buffer B contained the following protease and phosphatase inhibitors: 1 mM phenylmethylsulfonyl fluoride, 10 mM leupeptin, 50 trypsin
inhibitory milliunits of aprotinin, 1 mM 1,10-phenanthroline, 1 mM
pepstatin, 2.5 mM benzamidine hydrochloride, 100 mM sodium fluoride,
1 mM sodium vanadate, 30 mM sodium pyrophosphate, and 1 mM sodium molybdate. The protein content for all fractions was determined
with a BCA kit (Pierce) according to the manufacturer’s instructions.
Gel Electrophoresis and Immunoblotting—Proteins were separated
in 7.5 or 12% polyacrylamide (acrylamide from National Diagnostics)
gels containing sodium dodecyl sulfate (SDS) according to Laemmli (21)

and transferred to nitrocellulose (Bio-Rad) or Immobilon-P (Millipore)
in 25 mM Tris, 192 mM glycine, and 20% methanol. Following transfer,
the membrane was blocked in 4% nonfat milk for 1 h at room temperature. Results were visualized with horseradish peroxidase-conjugated
secondary antibodies (Sigma) and an enhanced chemoluminescence kit
(Pierce).
The antibody used for detection of the insulin receptor (R1064) was
generated against the C terminus deduced from the insulin receptor
(22). The anti-phosphotyrosine monoclonal antibody, 4G10, was purchased from Upstate Biotechnology, Inc. and used to detect insulin
receptor phosphorylation. The anti-phosphotyrosine monoclonal antibody, PY20, was purchased from Leinco and used to detect IRS-1
phosphorylation. A monoclonal antibody for GLUT4 (1F8), was used for
detection of the insulin-sensitive glucose transporter (23). Western
blots employing a monoclonal antibody were analyzed using goat antimouse antibody (Sigma) coupled to horseradish peroxidase followed by
chemoluminescence using the Renaissance system (Dupont NEN).
Blots using polyclonal antibodies were exposed to goat anti-rabbit (Sigma) coupled to horseradish peroxidase and visualized with
chemoluminescence.
Exogenous Kinase Activity Assays—The exogenous kinase activity of
the insulin receptor following its solubilization and partial purification
from cell extracts was determined as described previously (24). Briefly,
the insulin receptor was purified from total membranes by wheat germ
agglutinin-agarose affinity chromatography in the presence of the protease inhibitors and phosphatase inhibitors listed above. Bound receptor was eluted with 0.3 M N-acetylglucosamine in 20 mM HEPES (pH
7.4) containing 0.1% Triton X-100. The receptor was incubated with 50
mM ATP (100 mCi/ml [32P]ATP), 10 mM MgCl2, 8 mM MnCl2, and 2.5
mg/ml of poly(Glu:Tyr) (4:1) as a phosphate acceptor. Following a 10min incubation, the reaction was stopped by adding EDTA to a final
concentration of 67 mM. The reaction mixture was loaded on a 3 3 3-cm
piece of 3 M filter paper which was extensively washed with 10%
trichloroacetic acid and 100 mM pyrophosphate. Radioactivity incorporated into poly(Glu:Tyr) was determined as Cerenkov radiation in a
scintillation counter. For the final results, radioactivity was normalized
by the amount of the insulin receptor, which was determined by Western blot as described previously (24).
RNA Isolation and Analysis—Total RNA was isolated from the cells
by extraction with Trizol (Life Technologies, Inc.) and was prepared
according to the manufacturer’s instructions. Poly(A)1 RNA was selected using a poly(A)1 tract kit (Stratagene). For Northern blot analysis, 5 mg of poly(A)1 were separated by electrophoresis in 1.3% agarose,
2.0 M formaldehyde gels and transferred to Gene Screen Plus (Dupont
NEN). After ultraviolet cross-linking, filters were prehybridized, hybridized, and subjected to analysis as described previously (19). The
cDNAs utilized in these studies were as follows: GLUT4, the insulinsensitive glucose transporter (25); IRS-1, a generous gift from Dr.
Morris White (26); and b-actin, 1.9-kilobase HindIII fragment obtained
from Dr. D. W. Cleveland (27).
Determination of 2-Deoxyglucose—The assay of [3H]2-deoxyglucose
uptake was performed as described previously (19). Prior to the assay,
the cells were deprived of serum for 2– 4 h. Uptake measurement were
made in triplicate under conditions when hexose uptake was linear, and
the results were corrected for nonspecific uptake and absorption determined by [3H]2-deoxyglucose uptake in the presence of 5 mM cytochalasin B. Nonspecific uptake and absorption was always less than 10% of
the total uptake.
RESULTS

Effect of TNF-a on Insulin-sensitive Glucose Uptake—In
hepatocytes, it has been reported that TNF-a induces a defect
in insulin signaling in a time frame of less than 1 h (16, 17).
Thus, we examined the effect of relatively low (250 pM) and
high (1 nM) doses of TNF-a treatment on fully differentiated
3T3-L1 adipocytes over a 24-h time course. As shown in Table
I, low doses of TNF-a had essentially no effect on basal or
insulin-stimulated glucose uptake. Furthermore, insulin-stimulated glucose uptake was unaffected by 1 nM TNF-a following
cytokine treatment for 1 and 6 h (Table I). There may be a
slight decrease in insulin-stimulated glucose uptake in adipocytes exposed to the high doses of TNF-a for 24 h (7.8-fold
stimulation versus 9.2-fold, untreated). However, at this time,
GLUT4 protein is slightly diminished (data not shown), and the
basal uptake is slightly elevated (Table I). Thus, we observe no

TNF-a-induced Insulin Resistance in 3T3-L1 Adipocytes

973

TABLE I
Glucose transport activity
2-Deoxyglucose was determined at 22°C and corrected for nonspecific diffusion. The mean 6 S.D. (n 5 6) is shown.
250 pM TNF
Treatment

1000 pM TNF

Basal

Insulinstimulated

Fold
stimulation

160 6 7
153 6 9
161 6 2
175 6 9

1428 6 8
1398 6 13
1401 6 12
1418 6 9

8.9
9.1
8.7
8.1

Basal

Insulinstimulated

Fold
stimulation

1449 6 6
1362 6 6
1393 6 15
1388 6 7

9.2
8.9
8.8
7.8

pmol/min/mg protein

None
1h
6h
24 h

163 6 4
153 6 3
158 6 9
178 6 9

TABLE II
Glucose transport activity
2-Deoxyglucose was determined at 22°C and corrected for nonspecific diffusion. The mean 6 S.D. (n 5 6) is shown.
250 pM TNF 1 50 nM insulin

250 pM TNF
Treatment
Basal

Insulinstimulated

Fold
stimulation

160 6 7
175 6 9
181 6 4
191 6 7
202 6 6

1428 6 8
1418 6 9
1049 6 12
512 6 10
430 6 9

8.9
8.1
5.8
2.7
2.1

Basal

Insulinstimulated

Fold
stimulation

1445 6 9
1373 6 6
945 6 15
438 6 7
347 6 8

8.5
7.8
5.0
2.3
1.7

pmol/min/mg protein

None
24 h
48 h
72 h
96 h

significant compromise in insulin-stimulated glucose transport
in adipocytes exposed to relatively short treatments of TNF-a
and therefore, no lesion in insulin-dependent signal
transduction.
We also performed a longer time course of TNF-a treatment
under conditions previously shown to cause insulin-resistant
glucose uptake in fully differentiated 3T3-L1 adipocytes (28).
As in the cited study, maximal inhibition of insulin-sensitive
glucose uptake was not achieved until after 96 h of TNF-a
treatment (Table II). Only after 48 h of TNF-a exposure do the
adipocytes exhibit a significant decrease in insulin-stimulated
glucose uptake as compared to untreated cells (Table II). Furthermore, there is minimal synergistic action of TNF-a and
insulin when serum is supplemented with a high insulin concentration (Table II). Exposure to TNF-a for 96 h resulted in an
increase in basal glucose uptake, but more importantly, there
remained a 2–3-fold increase in insulin-stimulated glucose
transport even after 96 h of TNF-a exposure, thus indicating
the likelihood that insulin-dependent signal transduction pathway(s) remain intact at this time. TNF-a treatment for more
than 96 h did not result in a further decline of insulin-sensitive
glucose uptake (data not shown).
Effect of TNF-a on Components of the Insulin Receptor Signal Transduction Pathway—We next examined the effects of
TNF-a on the level of the insulin receptor, IRS-1, and GLUT4
proteins (Fig. 1) as well as on mRNA levels for the latter two
(Fig. 2). Fully differentiated 3T3-L1 adipocytes were treated for
0, 24, 72, or 96 h with 250 pM TNF-a, and total membranes
were probed by Western blotting with the appropriate antibody. Cytosolic fractions or whole-cell extracts were examined
for IRS-1 content, and the results were identical for both procedures (data not shown). Fig. 1 shows that TNF-a treatment
resulted in a slight decrease (;30%) in insulin receptor protein
after 96 h. However, there is a very significant decrease in both
GLUT4 and IRS-1 levels over this time. Both of these protein
decreased by 50 –70% after 72 h and were only 20% of controls
after 96 h of TNF-a exposure. The quantitative analysis of
these data was normalized against the content of secretory
component-associated membrane proteins, a set of proteins
known to be present in GLUT4 vesicles (29, 30) which are not
regulated by TNF-a in 3T3-L1 adipocytes (Fig. 1). Fig. 2 is a

170 6 6
176 6 3
189 6 9
192 6 9
209 6 11

representative Northern blot of IRS-1, GLUT4, and b-actin
mRNA expression in untreated adipocytes and in cells treated
with 250 pM TNF-a for 96 h. As expected and as normalized
against b-actin mRNA expression, IRS-1 and GLUT4 mRNA
from TNF-a-treated adipocytes are less than 20% of the levels
in untreated adipocytes.
The Effect of TNF-a on Insulin Receptor Phosphorylation and
Kinase Activity—It has been suggested that prolonged TNF-a
treatment (96 h or more) results in diminished insulin receptor
phosphorylation and kinase activity in adipocytes (13, 14). Accordingly, we examined insulin receptor amount and its ability
to undergo autophosphorylation in cells following 96 h of adipocyte exposure to various TNF-a doses. Fig. 3 shows that the
insulin receptor content diminishes slightly with exposure to
250 pM TNF (see also Fig. 1) and is more dramatically downregulated at higher cytokine doses (Fig. 3, bottom). However,
the tyrosine phosphorylation state of the insulin receptor from
TNF-a-treated cells was essentially unchanged (Fig. 3, top).
There is no insulin receptor autophosphorylation unless cells
are exposed to insulin, and when they are, they respond completely normally as determined by phosphotyrosine blotting
(Fig. 3, top). The autophosphorylation signal precisely corresponds to the amount of receptor, and they are diminished in
parallel in response to TNF-a treatment.
Fig. 4 depicts another experiment in which insulin receptors
were isolated from untreated and TNF-a-treated adipocytes by
wheat germ agglutinin chromatography (see under “Experimental Procedures”) and then examined for insulin receptor
content and phosphorylation state (top) by Western blotting.
We observed a small decrease in both receptor amount and
phosphorylation state (top) from the TNF-a-treated cells (see
also Fig. 3). We used the partially purified receptor to phosphorylate substrate (bottom) in the test tube, and because slightly
less receptor was isolated from the TNF-a-treated cells (top),
slightly lower substrate phosphorylation was seen (bottom).
When normalized to receptor amount, there is no difference in
the in vitro kinase activity or autophosphorylation state of
receptors isolated from untreated and TNF-a-treated adipocytes. We also performed an experiment using receptors purified from untreated and TNF-a-treated (96 h) adipocytes that
had not been exposed to insulin. Subsequent measurement of
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FIG. 1. TNF-a-treated adipocytes have reduced insulin receptor, IRS-1, and GLUT4 expression. Total membrane and cytosolic
fractions were prepared from fully differentiated 3T3-L1 adipocytes
treated with 250 pM TNF-a for 0, 24, 72, or 96 h. Proteins (75 mg/lane)
were separated by SDS-polyacrylamide gel electrophoresis, transferred
to Immobilon-P, and subjected to Western blot analysis with the appropriate antibody. The detection system was horseradish peroxidaseconjugated secondary antibodies and a chemoluminescence substrate
kit. The molecular mass of each protein is indicated to the left of the blot
in kilodaltons. The autoradiogram displayed is representative of an
experiment performed three times with independent cell preparations,
all of which gave similar results.

FIG. 2. IRS-1 and GLUT4 mRNA are down-regulated in TNF-atreated adipocytes. Poly(A)1 RNA was isolated from fully differentiated 3T3-L1 adipocytes that were not treated or were exposed to 250 pM
TNF-a for 96 h. Five mg of poly(A)1 RNA was electrophoresed and
subjected to Northern blot analysis. The same blot was sequentially
hybridized, stripped, and rehybridized with the indicated cDNA probes.
The IRS-1 blot was exposed for 6 days, GLUT4 for 6 h, and b-actin for
12 h. The sizes of the mRNAs are shown in kilobases (kb) to the left of
each panel. The autoradiogram displayed is representative of an experiment performed twice with independent RNA preparations.

FIG. 3. TNF-a causes a dose-dependent decrease in insulin
receptor amount but no change in the overall phosphorylation
state. A total membrane fraction was isolated from adipocytes that
were chronically (96 h) TNF-a-treated with the indicated doses of
TNF-a followed by a 10-min exposure to 100 nM insulin. Following
electrophoresis, the membrane preparations were examined for insulin
receptor amount and phosphorylation state using an anti-receptor and
anti-phosphotyrosine antibody, respectively. Detection was as described in Fig. 1. The molecular mass markers to the left of the blot are
in kilodaltons. The autoradiogram displayed is representative of experiments performed three times with independent cell preparations.

autophosphorylation and exogenous kinase activity gave identical results for receptors from TNF-a-treated and untreated
cells (data not shown).
The Effect of TNF-a on IRS-1 Tyrosine Phosphorylation—
From the previous figures, only the amount of protein and
mRNA for the various components of insulin-stimulated glucose uptake were shown to diminish in response to TNF-a.
However, the function of IRS-1 has also been suggested to be
altered in TNF-a-induced insulin resistance in adipocytes (13–
15). Therefore, we examined the insulin-dependent tyrosine
phosphorylation of IRS-1 in chronically TNF-a-treated adipo-

FIG. 4. The insulin receptor isolated from TNF-a-treated adipocytes phosphorylates poly(Glu:Tyr) identically to receptor
from untreated cells. Insulin receptors were partially purified by
wheat germ agglutinin chromatography as described under “Experimental Procedures” from untreated and TNF-a-treated (96 h) adipocytes exposed to insulin (1) or not (2) for 10 min. Receptor was then
used for Western blotting (A) as in the previous figure and was also used
to phosphorylate substrate (B) in the test tube. In B, the open bars
represent basal levels of phosphorylation and the solid bars represent
insulin stimulation. The exogenous kinase assay was performed as
described under “Experimental Procedures.” The results displayed are
representative of an experiment performed three times with independent cell preparations.

cytes (250 pM for 96 h). As also shown in Fig. 1, Fig. 5 shows
that TNF-a treatment results in significant loss of IRS-1 protein (.80%, top). IRS-1 tyrosine phosphorylation is diminished
to the same extent (bottom). Thus, as was the case for insulin
receptor autophosphorylation (Fig. 3), TNF-a diminishes the
amount of IRS-1, yet the remaining IRS-1 protein is tyrosinephosphorylated in a normal fashion in response to insulin.
Effect of TNF-a on GLUT4 Translocation—The prior data
(Figs. 1–5) coupled with the transport data of Table II suggests
no obvious lesion in insulin signaling in adipocytes due to
TNF-a exposure except for a decreased amount of the component proteins of the signaling pathway. As a further verification of this, we performed a GLUT4 translocation assay on
adipocyte membrane fractions (Fig. 6) on insulin-sensitive (untreated) and insulin-resistant (96 h of TNF-a exposure) 3T3-L1
adipocytes. The cells were exposed or not to insulin stimulation
(100 nM for 8 min) and then fractionated into membrane compartments. In insulin-treated adipocytes, there is an increase
in GLUT4 at the plasma membrane (PM), and a corresponding
decrease in internal membrane (IM) GLUT4, a result indicative of transporter translocation to the plasma membrane (31).
The level of GLUT4 protein present in the plasma membrane of
untreated cells is higher than expected from the transport data
of Table II but is consistent with many published studies that
indicate membrane fractionation of 3T3-L1 adipocytes is less
precise than that of rat adipocytes (e.g. see Ref. 20). In any case,
following 96 h of TNF-a exposure, GLUT4 levels were markedly diminished in both plasma membrane and internal membrane membrane fractions (top) as would be expected from
Figs. 1 and 2 and from previous studies (6, 10, 28). Nevertheless, when enough protein was loaded onto SDS-polyacrylamide gels and immunoblotted for GLUT4 protein (bottom), an
increase in the transporter at the plasma membrane is caused
by insulin exposure of TNF-a-treated adipocytes as is a depletion of GLUT4 from the internal membranes. Thus, GLUT4
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FIG. 5. TNF-a-treated adipocytes have a decreased IRS-1 content and a corresponding decrease in the overall tyrosine phosphorylation state. Cytosolic extracts were isolated from control and
TNF-a-treated adipocytes before or after acute stimulation with insulin
(100 nM for 8 min) Proteins (80 mg/lane) were separated by SDSpolyacrylamide gel electrophoresis, transferred to nitrocellulose, and
blotted for either IRS-1 or phosphotyrosine. Samples were processed
and results were visualized as described in Fig. 1. The molecular mass
markers to the left of the blot are in kilodaltons. The autoradiogram
displayed is representative of an experiment performed three times
with independent cell preparations.

FIG. 6. GLUT4 translocation occurs in TNF-a-treated adipocytes. Plasma membrane (PM) and intracellular membranes (IM) were
isolated from 3T3-L1 adipocytes that were either treated or not with
250 pM TNF-a for 96 h. Prior to isolation, all cells were serum-deprived
for 2 h and then exposed or not to 100 nM insulin for 8 min. Membrane
fractions were separated by SDS-polyacrylamide gel electrophoresis,
blotted with 1F8, and visualized as described under “Experimental
Procedures.” The molecular mass markers to the left of the blot are in
kilodaltons. The autoradiogram displayed is representative of an experiment performed four times with independent cell preparations.

translocation to the plasma membrane appears normal even
after prolonged exposure of fat cells to TNF-a, a result consistent with the glucose uptake data (Table II).
DISCUSSION

In general, the biochemical changes in cells brought about by
cytokines such as TNF-a are thought to occur as result of
altered gene expression, often due to activation of the STAT
(signal transducers and activators of transcription) family of
transcription factors (32, 33). Thus, the recent results from
several groups indicating that TNF-a may cause rapid (17, 18)
or slow (13–15) alterations in the ability of insulin to phosphorylate IRS-1 in hepatocytes (17, 18) and adipocytes (13–15)
prompted us to re-examine this process in 3T3-L1 adipocytes.
Previous studies with these cells indicated that TNF-a results
in insulin resistance after prolonged exposure to TNF-a (6, 10,
13, 14, 28) either as a result of GLUT4 down-regulation (6, 10,
28) or from diminished insulin receptor signaling, probably at
the level of IRS-1 tyrosine phosphorylation (13–15). On the
other hand, our current studies show no defect of the insulin
receptor in its ability to autophosphorylate in TNF-a-treated
adipocytes (Fig. 3) or in vitro after isolation from identically
treated adipocytes (Fig. 4). We also see no defect in IRS-1
tyrosine phosphorylation in TNF-a-exposed adipocytes (Fig. 5)
nor is the ability of the insulin receptor to phosphorylate a
synthetic substrate compromised after isolation from chronically TNF-a-treated (96 h) adipocytes (Fig. 4). Rather, we observe a global down-regulation of some of the known component proteins of insulin-stimulated glucose transport but not of
several control proteins (Figs. 1–3), in agreement with prior
results examining TNF-a-induced gene regulation in adipocytes (6). The remaining component proteins of the insulinstimulated glucose transport apparatus appear to function nor-
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mally at the level of both transport activation (Table II) and
GLUT4 translocation (Fig. 6).
We are at a loss to reconcile our current results with those
from very similar studies employing the same or similar cultured cell lines of murine adipocytes (14, 15). It is possible that
variations in the clonal nature of 3T3-L1 cells could give different results, and in addition, one of the published studies
used a different adipocyte cell line, 3T3-F442A cells, where a
loss of insulin sensitivity was detected prior to a loss in GLUT4
(14). One methodological difference between our studies and
those cited above (14, 15) is that, except for the experiment of
Table II, all of the figures we show here were from experiments
in which fat cells were exposed to TNF-a in the absence of
insulin, whereas Hotamisligil and colleagues performed their
experiments in the presence of this hormone (14, 15). The
reason that we generally omitted insulin from our studies is
that chronic exposure of 3T3-L1 adipocytes to insulin has long
been known to down-regulate insulin receptors (34). More recently, it has been shown that long term exposure of 3T3-L1 fat
cells to low doses of insulin causes a significant loss in the
cellular GLUT4 content (35) as well as a 70% decrease in IRS-1
protein which, nevertheless, is still tyrosine-phosphorylated in
response to insulin (36). As shown in Table II, the presence of
insulin during TNF-a exposure leads to a slight decrease in
insulin-stimulated glucose transport as compared to TNF alone
as early as 48 h after treatment. Similarly, we showed that the
effects of cytokine plus insulin on insulin receptor expression
was greater than cytokine alone, but receptor autophosphorylation and IRS-1 phosphorylation dropped in parallel (data not
shown), as they do for the TNF only condition (Figs. 3 and 5).
Since these results (Table II and data not shown) are in complete agreement with previously published studies of the effect
of insulin alone on its receptor, GLUT4, and IRS1 (34 –36), we
chose to present the novel observation that TNF-a alone has a
similar effect to insulin in down-regulating several components
of insulin-stimulated glucose transport in cultured fat cells.
On the other hand, we have no information concerning the
data from studies on hepatocytes in which TNF-a was shown to
affect insulin receptor function in a matter of minutes (17, 18).
In adipocytes, acute TNF-a treatment (15 min) or pretreatment
of TNF-a followed by insulin stimulation results in an enhancement of IRS-1 tyrosine phosphorylation and promotes its association with phosphatidylinositol 3-kinase (37). In the course of
our studies, we have also observed a very small enhancement of
IRS-1 tyrosine phosphorylation in adipocytes exposed to prolonged TNF-a treatment (data not shown). However, it has not
been demonstrated that IRS-1 is a mediator of TNF-a signal
transduction in any cell type.
Another question raised by our data concerns the nature of
the TNF receptor that mediates the effects we observe. There
are two cell surface TNF-a receptors, a type I receptor of Mr
55,000 and a type II species of Mr 75,000, that are present in all
cell types (38). Most biological actions of TNF-a are mediated
by the type I receptor (39), which in the case of murine cells is
the only receptor isotype that binds human TNF-a (40). As
indicated under “Experimental Procedures,” we performed all
our experiments with TNF-a from both species, and we obtained identical results, thus indicating that the type I receptor
is mediating the responses we observed in adipocytes. Very
recently, Peraldi et al. reached the same conclusion based on
the same protocol of comparing human and murine TNF-a
actions in 3T3-L1 cells (41).
In summary, we conclude that TNF-a-induced insulin resistance in 3T3-L1 adipocytes is not accompanied by a defect in
insulin receptor phosphorylation, IRS-1 tyrosine phosphorylation, or the ability of the insulin receptor to recruit GLUT4 to
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the plasma membrane. Our data indicate that the primary
mechanism of TNF-a action is likely to be at the level of
regulation of gene expression, the general mode of action for
cytokines (32, 33). This hypothesis is supported by previous
studies which demonstrate that short (2 h) exposure of 3T3-L1
adipocytes to TNF-a results in a .90% inhibition of GLUT4
transcription in the absence of protein synthesis (28). These
conclusions differ dramatically from other investigators (13–
15, 17, 18), and further studies are warranted to resolve both
the current discrepancies and the mechanism of action of TNF
in adipocytes.
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